Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Bahrain Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2026-2032) | Forecast, Industry, Size & Revenue, Trends, Value, Competitive Landscape, Outlook, Share, Growth, Companies, Analysis, Segmentation Market Forecast By GLP-1 Receptor Agonists (Exenatide, Liraglutide (Victoza), Lixisenatide (Lyxumia), Dulaglutide (Trulicity), Semaglutide (Ozempic)), By Insulin Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins) And Competitive Landscape In the Bahrain market, the import trend for insulin drugs and glucagon-like peptide 1 (GLP-1) receptor agonists showed a growth rate of 8.64% from 2023 to 2024
SURMOUNT-2 : This trial was particularly relevant for our friends with diabetes
If you suspect you are experiencing signs and symptoms of an overdose it's crucial to seek prompt medical attention
Because it is a strategy to boost treatment adherence and capture new patients
US$ 25.92
US$ 24.73
US$ 20.08
